Treatment of cystic fibrosis with soy derived isoflavones

用大豆异黄酮治疗囊性纤维化

• 批准号: 6575695
• 负责人: Gavin R Graff
• 金额: $ 6.54万
• 依托单位: UNIVERSITY OF MISSOURI-COLUMBIA
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-03-01 至 2003-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6575695
• 关键词: Treatment; cystic; fibrosis; soy; derived

The investigators propose to develop a aerosol delivery system containing genistein and a b-agonist (broncho-dilator) for the treatment of cystic fibrosis (CF). Preliminary studies have shown that genistein interacts with the CF transmembrane conductance regulator which is defective in patients with CF as a result of a specific mutation. Genistein raises the bioelectric potential difference (PD) across the nasal membrane and increases chloride transport. These investigations are directed at developing an aerosol by evaluating the dose and pharmacokinetics of genistein in regard to altering PD, performing a repetitive dose experiment with the aerosol, and finally performing safety studies with this aerosol. A final study will investigate the efficacy of using oral genistein supplements to alter the nasal membrane PD.

研究人员建议开发一种气雾剂输送系统 含有染料木黄酮和b-激动剂（支气管扩张剂），用于治疗 囊性纤维化（CF）。初步研究表明，染料木黄酮相互作用 CF跨膜传导调节器在患者中是有缺陷的 CF是一种特殊的突变。染料木黄酮提高生物电 跨鼻膜的电位差（PD）并增加氯化物 运输这些研究旨在通过以下方式开发气溶胶： 评价染料木黄酮改变PD的剂量和药代动力学， 用气雾剂进行重复剂量实验，最后 进行安全性研究。最后一项研究将调查 使用口服染料木黄酮补充剂改变鼻膜PD的功效。